NCT05768126View on ClinicalTrials.gov

Prediction of ECT Treatment Response and Reduction of Cognitive Side-effects Using EEG and Rivastigmine

PHASE4RecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 29, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

January 31, 2026

Conditions
Depressive Disorder
Interventions
DRUG

Rivastigmine Transdermal Product

The patches will be administered (first four weeks 4.6 mg and then 9.5. mg).

OTHER

Sham

The sham patches will be administered during the same period of time as the rivastigmine.

Trial Locations (1)

Unknown

RECRUITING

UMC Utrecht, Utrecht

All Listed Sponsors
collaborator

ZonMw: The Netherlands Organisation for Health Research and Development

OTHER

collaborator

St. Antonius Hospital

OTHER

collaborator

Tergooi Hospital

OTHER

lead

UMC Utrecht

OTHER